NCT06143566View on ClinicalTrials.gov

Polypill for Prevention of Cardiomyopathy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

September 1, 2027

Study Completion Date

December 1, 2027

Conditions
Type 2 DiabetesHigh Blood Pressure
Interventions
DRUG

Polypill

A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.

DRUG

Combined prescription of the individual medications

We will initiate participants on an ARB, SGLT2i, and Finerenone if they are not in the polypill arm.

Trial Locations (1)

75235

RECRUITING

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER